SEC For	m 4 FORM	4 U	NIT	ED STAT	٢Es	S SECI	JRIT	IFS	ΔΝΓ) EXCH4	ANGI		имія	SIO	N			
		Washington, D.C. 20549											OMB APPROVAL					
to Sec obligat	this box if no lo tion 16. Form 4 ions may contin tion 1(b).	or Form 5	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940										ΗP	IP OMB Number: 3235-0287 Estimated average burden hours per response: 0.5				
1. Name and Address of Reporting Person* Bhatia Sangeeta N.					V	2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title Other (specify below) below)				
(Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE					06	3. Date of Earliest Transaction (Month/Day/Year) 06/02/2021							C 1		,			
(Street) BOSTON MA 02210 (City) (State) (Zip))	4.	Line) X Fo Fo								Form Form	ual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)	(St		Zip)							D iana and				<u> </u>	1			
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Yee)					2A. Deemed Execution Date		3. Transa Code (8)	action	4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 an			d 5) Beneficia Owned Fo Reported		ount of ties cially I Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Code	v	Amount	(A) or (D)	Price		Transaction(s) (Instr. 3 and 4)				
Common Stock				06/02/2021				S ⁽¹⁾		285	D	\$208.9	96 ⁽²⁾⁽³⁾		,46 5	D		
Common Stock 06/0				06/02/202	1					153	D	\$210.0	.01 ⁽³⁾⁽⁴⁾		5,312	D		
Common Stock 06/02/202					1			S ⁽¹⁾		121	D	\$211	(3)(5)	5	5,191	D		
		Ta	ble I	ll - Derivati (e.g., pu						isposed o s, convert				Owned	ł		·	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution Date,			ransaction of Code (Instr. Derivat		ve (Mo es d	piratio	xercisable and n Date Day/Year)	Am Sec Und Der Sec	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		rice of ivative urity tr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownershi Form: y Direct (D) or Indirec (I) (Instr. 4	t (Instr. 4)	

Explanation of Responses:

1. Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1.

2. Open market sales reported on this line occurred at a weighted average price of \$208.96 (range \$208.64 to \$209.48).

3. Dr. Bhatia undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

(D)

(A)

v

Code

Date Exercisable

Expiration Date

Title

4. Open market sales reported on this line occurred at a weighted average price of \$210.01 (range \$209.64 to \$210.34).

5. Open market sales reported on this line occurred at a weighted average price of \$211.00 (range \$210.70 to \$211.50).

Remarks:

/s/ Sabrina Yohai, Attorney-in-06/04/2021 Fact

** Signature of Reporting Person Date

Amount or Number of Shares

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.